WO2019171352A3 - Methods of treating severe non-diabetic obesity - Google Patents
Methods of treating severe non-diabetic obesity Download PDFInfo
- Publication number
- WO2019171352A3 WO2019171352A3 PCT/IB2019/051915 IB2019051915W WO2019171352A3 WO 2019171352 A3 WO2019171352 A3 WO 2019171352A3 IB 2019051915 W IB2019051915 W IB 2019051915W WO 2019171352 A3 WO2019171352 A3 WO 2019171352A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- oxyntomodulin derivative
- treating severe
- severe non
- diabetic obesity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Disclosed herein are methods of treating severe non-diabetic obesity with an oxyntomodulin derivative conjugate administered once weekly at a dose of about 5 mg to about 10 mg. The oxyntomodulin derivative conjugate comprises an oxyntomodulin derivative comprising the amino acid sequence of SEQ ID NO: 2 and having a ring formation between residues 16 and 20; an IgG4 Fc region; and a polyethylene glycol, wherein the polyethylene glycol covalently links the oxyntomodulin derivative and the IgG4 Fc region.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862640463P | 2018-03-08 | 2018-03-08 | |
US62/640,463 | 2018-03-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019171352A2 WO2019171352A2 (en) | 2019-09-12 |
WO2019171352A3 true WO2019171352A3 (en) | 2019-11-07 |
Family
ID=66223762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2019/051915 WO2019171352A2 (en) | 2018-03-08 | 2019-03-08 | Methods of treating severe non-diabetic obesity |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019171352A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2710356T3 (en) | 2011-06-17 | 2019-04-24 | Hanmi Science Co Ltd | A conjugate comprising oxintomodulin and an immunoglobulin fragment, and use thereof |
PH12018501454A1 (en) | 2012-11-06 | 2020-02-17 | Hanmi Pharm Ind Co Ltd | Liquid formulation of protein conjugate comprising the oxyntomodulin and an immunoglubin fragment |
KR102418477B1 (en) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | Gluagon Derivatives |
WO2020128967A2 (en) * | 2018-12-19 | 2020-06-25 | Janssen Pharmaceutica Nv | Methods of treating severe non-diabetic obesity |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012173422A1 (en) * | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
WO2014017843A1 (en) * | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
WO2014073845A1 (en) * | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
WO2016043533A1 (en) * | 2014-09-16 | 2016-03-24 | Hanmi Pharm. Co., Ltd. | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
-
2019
- 2019-03-08 WO PCT/IB2019/051915 patent/WO2019171352A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012173422A1 (en) * | 2011-06-17 | 2012-12-20 | Hanmi Science Co., Ltd. | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof |
WO2014017843A1 (en) * | 2012-07-25 | 2014-01-30 | Hanmi Pharm. Co., Ltd. | Composition for treating hyperlipidemia comprising oxyntomodulin derivative |
WO2014073845A1 (en) * | 2012-11-06 | 2014-05-15 | Hanmi Pharm. Co., Ltd. | A composition for treating diabetes or diabesity comprising oxyntomodulin analog |
WO2016043533A1 (en) * | 2014-09-16 | 2016-03-24 | Hanmi Pharm. Co., Ltd. | Use of a long acting glp-1/glucagon receptor dual agonist for the treatment of non-alcoholic fatty liver disease |
Non-Patent Citations (11)
Title |
---|
ANONYMOUS: "2017-003616-39: A Randomized, Double-blind Placebo-controlled and Open-label Active-controlled, Parallel-group, Multicenter, Dose-ranging Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Subjects", 13 March 2018 (2018-03-13), pages 1 - 5, XP055612057, Retrieved from the Internet <URL:https://www.clinicaltrialsregister.eu/ctr-search/trial/2017-003616-39/SE> [retrieved on 20190809] * |
ANONYMOUS: "Disposicion N° 05458", 17 July 2017 (2017-07-17), pages 1 - 8, XP055612052, Retrieved from the Internet <URL:http://www.anmat.gov.ar/boletin_anmat/mayo_2017/Dispo_5458-17.pdf> [retrieved on 20190809] * |
ANONYMOUS: "HM 12525A - AdisInsight", 14 October 2017 (2017-10-14), pages 1 - 4, XP055612030, Retrieved from the Internet <URL:http://web.archive.org/web/20171014193308/https://adisinsight.springer.com/drugs/800040692> [retrieved on 20190809] * |
ANONYMOUS: "International Nonproprietary Names for Pharmaceutical Substances (INN)", WHO DRUG INFORMATION, vol. 31, no. 4, 19 January 2017 (2017-01-19), pages 635 - 754, XP055612042 * |
ANONYMOUS: "NCT03486392: A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants", 30 March 2018 (2018-03-30), pages 1 - 9, XP055612060, Retrieved from the Internet <URL:https://clinicaltrials.gov/ct2/history/NCT03486392?V_1=View#StudyPageTop> [retrieved on 20190809] * |
DATABASE REGISTRY [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 8 January 2017 (2017-01-08), ANONYMOUS: "Efinopegdutide", XP002793492, retrieved from STN Database accession no. 2055640-93-0 * |
J KANG ET AL: "791: The ultra-long acting LAPSGLP/GCGdual agonist,HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study", ABSTRACTS OF 51ST EASD ANNUAL MEETING, vol. 58, 1 September 2015 (2015-09-01), pages S380 - S381, XP055611972 * |
JAHOON KANG ET AL: "The ultra-long acting LAPS GLP/GCG dual agonist, HM12525A, demonstrated safety and prolonged pharmacokinetics in healthy volunteers: a phase 1 first-in-human study PS-069-791 REFERENCES", 23 September 2015 (2015-09-23), pages 1 - 2, XP055612020, Retrieved from the Internet <URL:http://www.hanmipharm.com/ehanmi/img/rnd/2015_EASD_(HM12525A).pdf> [retrieved on 20190809] * |
JI-HEE HA ET AL: "Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins", FRONTIERS IN IMMUNOLOGY, vol. 7, 6 October 2016 (2016-10-06), pages 1 - 16, XP055377975, DOI: 10.3389/fimmu.2016.00394 * |
S JUNG ET AL: "790: Potent weight loss mechanism and improvement of NASH by the long-acting GLP-1/glucagon receptor dual agonist HM12525A", ABSTRACTS OF 51ST EASD ANNUAL MEETING, vol. 58, 1 September 2015 (2015-09-01), pages S380 - S381, XP055611969, DOI: 10.1007/s00125-015-3687-4 * |
SY JUNG ET AL: "A Novel Long-Acting GLP-1/Glucagon Dual Receptor Agonist: Potent Weight Loss Mechanism and Improvement of NASH by HM12525A", 75TH ANNUAL SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION, 6 June 2015 (2015-06-06), pages 1, XP055611892 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019171352A2 (en) | 2019-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019171352A3 (en) | Methods of treating severe non-diabetic obesity | |
JP2024026108A (en) | Anti-transferrin receptor antibodies and uses thereof | |
NZ708105A (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
JP6709844B2 (en) | Molecular constructs for treating transplant rejection | |
JP2022037244A (en) | Multivalent fragments of antibody 3e10 and methods of use thereof | |
WO2011149964A3 (en) | Methods for treating or preventing vascular graft failure | |
EP2532365A4 (en) | Pharmaceutical composition for treatment and/or prevention of cancer | |
US11779653B2 (en) | Multi-armed polyrotaxane platform for protected nucleic acid delivery | |
WO2016154621A1 (en) | SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF | |
JP2018523686A5 (en) | ||
WO2007097903A3 (en) | Hiv fusion inhibitor peptides with improved biological properties | |
EP2758432B1 (en) | Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile | |
JP2016531915A5 (en) | ||
JP2018522563A5 (en) | ||
WO2006056464A3 (en) | Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4) | |
WO2021044208A8 (en) | Antibody-drug conjugate comprising antibody against human ror1, and use for the same | |
NZ591130A (en) | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof | |
EP2532366A4 (en) | Pharmaceutical composition for treating and/or preventing cancer | |
WO2012142320A8 (en) | Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition | |
EP2594582A3 (en) | Peptide vaccines with Seq Id No: 110, 111, 387, 112, 394 114, 116, 117 or 121 for cancers expressing tumor-associated antigens | |
JP2009519025A5 (en) | ||
TW201818075A (en) | Conditionally active polypeptides and methods of generating them | |
WO2009059309A2 (en) | Furin-cleavable peptide linkers for drug-ligand conjugates | |
JP2014502955A5 (en) | ||
WO2004064787A3 (en) | Parenteral formulations of peptides for the treatment of systemic lupus erythematosus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19718449 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 19718449 Country of ref document: EP Kind code of ref document: A2 |